Oscar Health, Inc. (OSCR): what the price assumes

boothcheck covers Oscar Health, Inc. (OSCR) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/OSCR

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The implied return on book is non-physical at this price-to-book and is suppressed as misleading. The price sits beyond a 17.7% return on equity sustained for 40 years and is not resolvable as a sustainable-ROE point. The rarity read below is the honest signal.

How unusual the bet is: extreme

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=2)

Economic-Unit Decomposition (Sum Of The Parts)

The issuer is a funded financial business. Debt, interest, and cash flows are operating inputs, so industrial EV, net-debt, WACC, and free-cash-flow lenses do not apply; value the common-equity claim with book, earnings, capital, and payout economics.

No unit-level total common-equity value is stated. Each financial unit requires supported standalone common equity, normalized earnings, capital adequacy, and payout capacity. Consolidated debt, interest, and cash are operating balances, not an enterprise-to-equity bridge; company-level book, earnings, capital, and payout lenses remain the coherent cross-checks.

Solvency

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

• The one number that decides Oscar is the medical loss ratio. Q1 2026 came in at 70.5%, and full-year guidance sits at 82.4% to 83.4%. The whole bull-versus-bear argument is whether the company keeps claims below the premiums it collects as it scales.
• The price asks a lot of the balance sheet. At about 5.6x book, the multiple sits at the very top of the peer group and embeds a return on capital so high it cannot be expressed as a single sustainable figure. That is the disconnect: a thin equity base carrying a rich price.
• The recent results are genuinely strong. Q1 2026 revenue rose 53% to $4.65 billion, membership reached 3.17 million, and the company posted record quarterly profit. Full-year guidance is for $18.7 billion to $19.0 billion of revenue and $250 million to $450 million of operating earnings.

Bull Case

The single metric that flips Oscar's entire verdict is the medical loss ratio, the share of premiums paid out as claims. In Q1 2026 it came in at 70.5%, and management guides the full year to 82.4% to 83.4% (Oscar Q1 2026 transcript, AOL). For a health insurer, that one ratio is the difference between a scaling profit machine and a cash incinerator, and Oscar has moved it to a level where the business finally earns money. The company describes its model in its own filing as built on engagement, high-value clinical care, and the trust of its effectuated members (FY2025 10-K, accession 0001568651-26-000011). When that engagement model holds the loss ratio down while membership climbs, the operating leverage is dramatic.

The growth underneath the ratio is the second leg of the bull case. Q1 2026 revenue rose 53% year over year to $4.65 billion, driven by membership that reached 3.17 million and by rate actions, and the quarter produced record profitability (Simply Wall St). This is a company adding members at better than 50% a year while improving margins at the same time, which is the rare combination that justifies paying up. Management reaffirmed full-year guidance of $18.7 billion to $19.0 billion in revenue with operating earnings of $250 million to $450 million, so the profit is not a one-quarter accident.

The forward-looking valuation methods reach the price where the static ones cannot, and that is the correct read for a business at this stage. The relative and forward-growth families bracket the $28.39 price (Relative Valuation at $28, P/Sales Sector at $28, Discounted Future Market Cap at $41), while the FCF-based methods land well above it. Oscar is also building optionality beyond its core book: a CMS-approved carrier-agnostic Lucie Health Marketplace, an ICHRA platform, and AI-driven operations including bilingual voice agents. If the ACA marketplace stays intact and Oscar keeps converting membership growth into controlled loss ratios, the technology-led cost structure is the structural edge that the legacy insurers, priced on book value, do not have.

Bear Case

Start with the qualitative disconnect, not the ratio: Oscar is being priced as a proven compounder while its balance sheet is still that of a young insurer that only recently turned profitable. The price sits at roughly 5.6x book, at the very top of its peer group, and that multiple embeds a return on capital so far above anything historically sustainable that it cannot honestly be stated as a single number. The asset-based methods make the gap concrete: the book-value floor lands near $5 against a $28.39 price (June 27, 2026). You are paying more than five times the company's net worth for an earnings stream that has existed for a short time.

The medical loss ratio that powers the bull case is also the bear case, because it is volatile and largely outside the company's control. Q1 ran a flattering 70.5%, but management's own full-year guide steps it up to 82.4% to 83.4%, with the highest reading in Q4. ACA marketplace economics swing on risk-adjustment accruals, regulatory changes to subsidies, and the health of the membership pool, and Oscar already flagged that Q1 revenue was partly offset by a higher risk-adjustment payable accrual (Oscar Q1 2026 transcript, AOL). A single bad season of claims, or a policy change to ACA subsidies, can erase a year of profit in a business with this little equity cushion.

The concentration and policy risk compound the thin-capital problem. Oscar is overwhelmingly an ACA individual-marketplace insurer, so its fate is tied to a single regulatory program whose subsidy structure is perennially contested in Washington. Its peer cohort here, a mix of care-delivery and healthcare-services names, underlines that Oscar is not a diversified managed-care company with employer and government books to lean on. The forward-growth models that justify the price all assume the membership ramp continues and the loss ratio behaves; the asset and earnings-power frames, which assume neither, say the stock is several times too expensive.

Valuation

Oscar is a clean example of a price that only the forward-looking methods can reach. Because it is an insurer, value is read off return on capital and price-to-book rather than an operating multiple, and on that lens the read is stark: at about 5.6x book the price implies a return on capital so far above any sustainable record that the model suppresses the implied figure as misleading rather than print a non-physical number. The price-to-book sits at the very top of the peer group, and a sustained return at the implied level is vanishingly rare historically. That is why the priced-in assumption carries the most demanding characterization on the scale.

The model dispersion tells the same story. The relative and forward-growth families sit near or above the $28.39 price (Relative Valuation $28, P/Sales Sector $28, Discounted Future Market Cap $41, and the FCF-yield methods far higher on a strong recent cash flow), while the asset-based methods sit far below it, with the book-value floor near $5. The honest summary is that this is a bet on the durability of a recently achieved profitability, priced at a multiple of book that no historical return record supports. The reverse-DCF could not solve to a reliable fair-value range, which is itself the signal: the price is at the edge of what the framework can rationalize, and the entire case rests on the medical loss ratio staying in check as the company scales.

Catalysts

Oscar reported Q1 2026 results with revenue of $4.65 billion (up 53% year over year), net income of $679 million, diluted EPS from continuing operations of $2.07, and a Q1 medical loss ratio of 70.5%, alongside membership of 3.17 million (Oscar Q1 2026 transcript, AOL). The stock has roughly doubled in 2026, with shares rising on the record profit and again on a leadership shift and an analyst upgrade (Yahoo Finance).

The forward setup is dominated by the loss-ratio path and by ACA policy. Management reaffirmed full-year 2026 guidance of $18.7 billion to $19.0 billion in revenue, a medical loss ratio of 82.4% to 83.4%, an SG&A expense ratio of 15.8% to 16.3%, and earnings from operations of $250 million to $450 million (Simply Wall St). The key catalysts are the quarterly loss-ratio prints stepping up through the year as guided, the open-enrollment membership cycle, the rollout of new platforms (Lucie Health Marketplace, ICHRA X, and AI-driven operations), and above all any legislative action on ACA subsidies, which is the single external variable with the most leverage over the thesis.

Peer Cohorts (Per Segment, With Filing Citations)

Health insurance & +Oscar platform (reported)

• MOH (MOLINA HEALTHCARE, INC.)
• FY2025 10-K: …in Los Angeles, Riverside/San Bernardino, Sacramento, and San Diego counties and significantly expanded our footprint in Los Angeles County. Our California Medicaid contracts represented premium revenue of approximately $4,170 million, or 13%, of our consolidated Medicaid premium revenue in 2025. New York. Our…
• FY2025 10-K: …insurance coverage for employees working 30 hours or more per week; • 401(k) employer matching contributions of up to 100% on the first 4% contributed by the employee; • Personal time off that provides employees with paid time away from work, combining vacation and sick leave; • Paid parental leave to support bonding…
• ALHC (ALIGNMENT HEALTHCARE, INC.)
• FY2025 10-K: …and cost effective. Competition The U.S. healthcare insurance industry is highly competitive. Our competitors vary by local market and include other managed care companies, national insurance companies, HMOs and PPOs. Many of our competitors have a larger membership base and/or greater financial resources than we do.…
• FY2025 10-K: …accruing to CMS and the federal government. These savings allow high-performing plans to offer enhanced supplemental benefits-such as lower cost sharing, $0 premium Part D coverage, and additional supplemental services-at no additional cost to the senior. CMS also evaluates Medicare Advantage plans through a Five…
• CLOV (CLOVER HEALTH INVESTMENTS, CORP. /DE)
• FY2025 10-K: …and industry expectations, new product offerings and constantly evolving beneficiary and provider preferences and user requirements. We face competition from incumbent MA sponsors, many of whom are developing their own technology or partnering with third-party technology providers to drive improvements in care. Our…
• FY2025 10-K: …Clover is the plan for consumers We believe that an approach focused on consumer healthcare choice, enhanced provider trust, and competitive pricing results in distinct value to our members and makes great healthcare available to everyone. • Provider of choice. We value the health decisions our members make and…
• CNC (CENTENE CORPORATION)
• FY2025 10-K: …2026 Marketplace membership and continue to increase the overall morbidity of the Marketplace population. During the third quarter of 2025, we reacted to an evolving regulatory and market environment and took corrective pricing actions for 2026 in states covering 95% of Marketplace membership. We continue to advocate…
• FY2025 10-K: …improvements in quality and health outcomes, healthcare costs and member satisfaction. High-quality provider support and service levels are important as our key customers are increasingly using performance-based measures to select and pay health plans. We have a suite of network performance tools for use by…
• HUM (HUMANA INC)
• FY2025 10-K: …income (loss) from operations, to assess performance and allocate resources primarily during our annual budget process and periodic forecast updates. For additional information on our business segments and 4 segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included in…
• FY2025 10-K: • Long-term care insurance • Weekly paid well-being time • Whole-person well-being and rewards programs and platform • On-demand fitness classes, nutritional education through teaching kitchens, and digital coaching apps • Incentives for engaging in well-being programs Life • Paid time off, paid holidays, paid…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.